susan berger, ph.d.
Susan is a Compass Strategies consultant specializing in risk assessment and regulatory issues. Previously, she served as Pfizer's Worldwide Head for Safety & Regulatory Intelligence, as Director of Risk Management Strategy and as the chief of staff to Pfizer's Chief Medical Officer. In these roles, Susan was responsible for Pfizer's risk strategy development and dealing with the FDA, as well as managing operations for a 2,000 employee division of Pfizer.
Prior to joining Pfizer, Susan was an associate director of corporate licensing for Merck. In this role, Susan conducted evaluations of proposed licensing agreements and assessed the strategic and operational needs of Merck's potential licensing partners. Susan was also responsible for developing alternative financial structures based upon particular partners' needs.
Before entering the private sector, Susan was the recipient of a MacArthur Foundation grant and worked in the U.S. Department of State's Politico-Military Bureau. While at the State Department, she represented the United States in international arms control negotiations and developed talking points and congressional testimony on arms control policies for then-Secretary of State James Baker.
After leaving the State Department, Susan served as senior chemical policy analyst for the U.S. Department of Commerce, where she was responsible for establishing export control procedures for chemicals and biologics. In this role, Susan also served as the Commerce Department's liaison to pharmaceutical industry executives on reporting obligations under international treaties.
Susan graduated summa cum laude with a B.S. from the University of Connecticut, earned a Ph.D. in physical chemistry from Stanford University and a M.B.A from Harvard University. She is a past chair of the Alliance for Biosecurity and is a member of the Harvard Business School Health Industry Alumni Association.
Prior to joining Pfizer, Susan was an associate director of corporate licensing for Merck. In this role, Susan conducted evaluations of proposed licensing agreements and assessed the strategic and operational needs of Merck's potential licensing partners. Susan was also responsible for developing alternative financial structures based upon particular partners' needs.
Before entering the private sector, Susan was the recipient of a MacArthur Foundation grant and worked in the U.S. Department of State's Politico-Military Bureau. While at the State Department, she represented the United States in international arms control negotiations and developed talking points and congressional testimony on arms control policies for then-Secretary of State James Baker.
After leaving the State Department, Susan served as senior chemical policy analyst for the U.S. Department of Commerce, where she was responsible for establishing export control procedures for chemicals and biologics. In this role, Susan also served as the Commerce Department's liaison to pharmaceutical industry executives on reporting obligations under international treaties.
Susan graduated summa cum laude with a B.S. from the University of Connecticut, earned a Ph.D. in physical chemistry from Stanford University and a M.B.A from Harvard University. She is a past chair of the Alliance for Biosecurity and is a member of the Harvard Business School Health Industry Alumni Association.